We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where DBV Technologies S.A. (NASDAQ:DBVT) stands against other healthcare stocks that are surging in 2025.
After lagging behind the broader market in 2024, many healthcare stocks are making a comeback this year. Healthcare spending has been continuously soaring and is projected to do so in the coming years due to demographic tailwinds. The industry now accounts for a fifth of the U.S. economy, and it’s a good idea to have exposure to it.
Most executives now hold a favorable view of the industry’s prospects, a notable increase from 52% just a year ago. Moreover, it’s an industry that is more insulated from tariffs and macro risks.
Of course, the top gainers here are not defensive healthcare stocks, but it’s still worth looking into the winners here if you are chasing potential multibaggers.
Even during bear markets, there are pockets of the market that perform exceptionally well. For example, I identified 15 Energy Stocks that are Up the Most in 2025 in another article.
Methodology
For this article, I screened the best-performing healthcare stocks year-to-date.
I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A scientist wearing a lab coat looking into a microscope examining a biopharmaceutical sample.
DBV Technologies S.A. (NASDAQ:DBVT)
Number of Hedge Fund Holders In Q4 2024: 5
DBV Technologies S.A. (NASDAQ:DBVT) is a clinical-stage biopharmaceutical company developing non-invasive, self-administered therapies for food allergies, most notably the Viaskin Peanut Patch for children.
The stock is up significantly so far in 2025 as the company announced a pivotal agreement with the FDA. The FDA accepted positive safety data from the VITESSE Phase 3 study and allowed DBV Technologies S.A. (NASDAQ:DBVT) to bypass an additional COMFORT trial, fast-tracking its Biologics License Application for the Viaskin Peanut Patch. This outcome could accelerate the product’s market release by up to a year and significantly de-risk the regulatory path.
On the same day, DBV Technologies S.A. (NASDAQ:DBVT) also secured up to $306.9 million in new financing, with $125.5 million received immediately and the remainder contingent on warrant exercises. This capital infusion was earmarked to support the Viaskin Peanut program, regulatory submissions, and potential commercialization, but it came with the caveat of significant dilution for existing shareholders.
The consensus price target of $22.5 implies 163.77% upside.
DBV Technologies S.A. (NASDAQ:DBVT) stock is up 176.05% year-to-date.
Overall, DBVT ranks 6th on our list of healthcare stocks that are surging in 2025. While we acknowledge the potential of DBVT as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than DBVT but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Hedge Fund Resource Center